Bristol Sells ConvaTec Wound Care For $4.1 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
Sale represents Bristol’s latest effort to sharpen its focus on drugs.
You may also be interested in...
Pharma's Strategic Divide: Focus or Diversify
It looks like the biggest strategic gulf in the industry: focus or diversify? If the CEO thinks he can't rely on R&D to grow his way out of the industry's revenue hole, get ready to live alongside generics and OTC businesses--though he'll downplay to investors the risks of managing different businesses by stressing the commonalities with the core branded efforts and probably won't move into wholly non-pharma businesses. If he's still committed to R&D--get ready for diversification of other sorts, and some pretty clever financial tactics.
BMS Licenses Kai Heart Drug For $227 Million
Delta protein kinase C inhibitor was given up by Daiichi Sankyo in 2007.
BMS Licenses Kai Heart Drug For $227 Million
Delta protein kinase C inhibitor was given up by Daiichi Sankyo in 2007.